Since the novel Coronavirus became a pandemic, the focus of governments, the World Health Organization, and multilateral agencies, has been on the need to “flatten the curve”.
With top pharmaceutical research houses racing to get a vaccine. Herein, we examine the prospect for early development of a vaccine.
According to widespread medical opinions, the development of a vaccine is a long and complex process that takes between 10-15 years.
Given the dire situation of the world, researchers and pharmaceutical companies are racing to develop a vaccine as soon as possible.
Reports have it that medical researchers have been able to cut the time between the exploratory stage and clinical stage significantly and 123 different possible vaccines are in the pre-clinical stage while 10 are in clinical stage.
The question remains how soon can we get a vaccine?
No doubt, regulators are ready to speed up the process of a vaccine approval. However, ample time must be given in conducting clinical tests and human trials to ensure that harmful drugs are not released to the public.
Bearing the above in mind, the most optimistic case is that a vaccine will be available by June 2021.
Notably, Janssen Pharmaceutical Companies, a subsidiary of Johnson & Johnson anticipates that the first batches of a COVID-19 vaccine could be available for emergency use and authorization in early 2021.
Overall, with the faint prospect of a vaccine in H2-2020, economic activities are expected to remain at a record low for the rest of the year.
United Capital Plc Research